Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen's net sales of Tecfidera® or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the Opposition Proceeding, including any appeal thereto.
Company profile
Ticker
FWPAY
Exchange
Website
CEO
Claus Svendsen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
FWPAY stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
24 Jan 23
POS AM
Prospectus update (post-effective amendment)
20 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jan 23
15-12G
Securities registration termination
17 Jan 23
6-K
Current report (foreign)
13 Jan 23
25-NSE
Exchange delisting
6 Jan 23
6-K
Current report (foreign)
28 Dec 22
6-K
Current report (foreign)
19 Dec 22
6-K
Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review
6 Dec 22
Latest ownership filings
SC 13G/A
Rosetta Capital I, LP
14 Feb 23
SC 13G
StepStone Group LP
29 Dec 22
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 22
SC 13G/A
Newtyn Management, LLC
16 Feb 21
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
11 Feb 21
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G
Forward Pharma A/S
14 Feb 20
SC 13G/A
Forward Pharma A/S
14 Feb 19
SC 13G/A
Forward Pharma A/S
4 May 18
SC 13G/A
Forward Pharma A/S
9 Feb 18
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 371.67 mm |
Total shares | 15.49 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 10.19 mm | $71.67 mm |
Rosetta Capital I | 5.30 mm | $0.00 |
Mason Capital Management | 525.00 | $300.00 mm |